

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark, Office Address: COMMISSIONER FOR PATENTS Adexandris, Virginia 22313-1450 www.kusplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/606,589	06/26/2003	Julian P. Breillatt JR.	CRTS-5652 DIV	5062
7590 10/23/2003			EXAMINER	
BAXTER HEALTHCARE CORPORATION			KIM, SUN U	
One Baxter Parkway DF3-3E Deerfield II 60015			ART UNIT	PAPER NUMBER

DATE MAILED: 10/23/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
,	10/606,589	BREILLATT ET AL.			
Office Action Summary	Examiner	Art Unit			
,	John Kim	1723			
The MAILING DATE of this communication ap					
Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (8) MONTHS from the mailing date of this communication. - If the period for reply secofied above, the maximum statutory period will apply and will expire SIX (8) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status					
1) $oxed{\boxtimes}$ Responsive to communication(s) filed on $\underline{26}$	Responsive to communication(s) filed on 26 June 2003.				
2a)☐ This action is FINAL. 2b)☑ T	his action is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims					
4)⊠ Claim(s) <u>1-4</u> is/are pending in the application.					
4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.					
6)⊠ Claim(s) <u>1-4</u> is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) are subject to restriction and/or election requirement.					
Application Papers					
9)☐ The specification is objected to by the Examiner.					
10)⊠ The drawing(s) filed on <u>26 June 2003</u> is/are: a)⊠ accepted or b)⊡ objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
11) The proposed drawing correction filed on is; a) approved b) disapproved by the Examiner.					
If approved, corrected drawings are required in reply to this Office action.					
12)☐ The oath or declaration is objected to by the Examiner.					
Priority under 35 U.S.C. §§ 119 and 120					
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).					
a) ☐ All b) ☐ Some * c) ☐ None of:					
1. Certified copies of the priority documents have been received.					
2. Certified copies of the priority documents have been received in Application No					
 Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).					
a) ☐ The translation of the foreign language provisional application has been received. 15)☑ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.					
Attachment(s)					
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) (5) Notice of Informa	ary (PTO-413) Paper No(s) al Patent Application (PTO-152)			
JS. Patent and Trademark Office PTOL-326 (Rev. 04-01) Office A	action Summary	Part of Paper No. 101603			

Application/Control Number: 10/606,589

Art Unit: 1723

1. The disclosure is objected to because of the following informalities: U.S. Patent

Application Serial No. 09/624,308 filed 24 July 2000 on lines 4-6 of page 1 needs to be updated to show that the application has been issued as U.S. Patent No. 6,612,447.

Appropriate correction is required.

- 2. Information Disclosure Statement filed on 6/26/03 has been considered by the examiner.
- The following is a quotation of the second paragraph of 35 U.S.C. 112:
 The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
- 4. Claims 3-4 provides for the use of the blood filter, but, since the claim does not set forth any steps involved in the method/process, it is unclear what method/process applicant is intending to encompass. A claim is indefinite where it merely recites a use without any active, positive steps delimiting how this use is actually practiced.
- 5. Claims 3-4 are rejected under 35 U.S.C. 101 because the claimed recitation of a use, without setting forth any steps involved in the process, results in an improper definition of a process, i.e., results in a claim which is not a proper process claim under 35 U.S.C. 101. See for example *Ex parte Dunki*, 153 USPQ 678 (Bd.App. 1967) and *Clinical Products, Ltd.* v. *Brenner*, 255 F. Supp. 131, 149 USPQ 475 (D.D.C. 1966).
- 6. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Application/Control Number: 10/606,589

Art Unit: 1723

- 7. Claims 1-4 are rejected under 35 U.S.C. 103(a) as being unpatentable over European Patent Application No. 406,485 (hereinafter referred to as EP '485. EP '485 teaches a filter for removing leukocytes from blood comprising a housing (7, 10) and a filter media (9) in the housing connected to a blood reservoir (2) (see figure 3) including an asymmetric membrane having a continuous porous structure and having first surface of the membrane having pore diameters smaller than the second surface wherein the pore diameters of the first surface is 14 microns and increasing toward the second surface with a pore size of 17, 21, 43 microns (see figures 4-9; abstract; col. 3, lines 52-57; col. 4, lines 17-30; col. 8, lines 13-44). Claims 1-4 essentially differ from the filter of EP '485 in reciting the majority of open area formed by cells intersecting the first skin surface having pore diameter of between about 12 microns and 28 microns. EP '485 teaches that leukocytes have a diameter of about 6 to 12 microns and filter with average pore size of about 6-14 microns and even pore sizes of 21-43 microns removes leucocytes (see col.7, lines 24-49). It would have been obvious to one having ordinary skill in the art at the time the invention was made to optimize the range of given pore size of the cells to effectively remove leukocytes, since it has been held that where the general conditions of a claim are disclosed in the prior art, discovering the optimum or workable ranges involves only routine skill in the art. In re Aller, 105 USPQ 233.
- 8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to John Kim whose telephone number is (703) 308-2350. The examiner can normally be reached on weekdays from 7:00 AM 3:00 PM.

Page 3

Application/Control Number: 10/606,589

Art Unit: 1723

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Wanda Walker, can be reached on (703) 308-0457. The fax phone number for official response is (703) 872-9306.

When sending a draft amendment by fax, please mark the paper as "DRAFT"; otherwise, mark the paper "OFFICIAL". This will expedite the processing of the paper.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0651.

John Kim

Primary Examiner

Art Unit 1723

J. Kim October 16, 2003